AstraZeneca Explored Buying Bristol Myers in Potential Mega Merger

AstraZeneca reportedly explored acquiring Bristol Myers Squibb in what would be a rare cross-Atlantic mega-merger, according to Bloomberg UK. The brief update indicates the British firm looked at a potential purchase of the U.S. company, though it does not say whether talks progressed or resulted in an offer. Such a deal, if it materialized, would combine two large drugmakers with major portfolios, potentially reshaping competitive dynamics in areas like oncology and immunology. The report is framed as part of the day’s breaking business news but provides few additional details in the excerpt provided.